For the precise diagnosis of people with chronic hepatitis B (CHB), a research team has created a test that combines highly sensitive coamplification at lower denaturation temperature polymerase chain reaction (COLD-PCR) with probe-based fluorescence melting curve analysis (FMCA). The straightforward, affordable test might be applied frequently in medical labs.
The hepatitis B virus (HBV) can be fatal and affects the liver; it typically results from cirrhosis or liver cancer. Contact with infected blood or bodily fluids is the most common way for the virus to propagate. Vaccines that provide nearly complete protection against HBV infection can avoid HBV.
According to recommendations, it is crucial to monitor HBV DNA, genotypes, and reverse transcriptase dynamically (RT) mutant DNA to determine a patient’s infection status, forecast the course of their illness, and evaluate the effectiveness of their therapy. They think COLD-PCR/ fluorescence melting curve analysis (FMCA) offers a potent laboratory instrument for accurate HBV-infected patient diagnosis and treatment.
Although several molecular techniques have been created to measure these parameters, many have poor sensitivity or need help identifying multiple mutations simultaneously. Others are too costly or complicated for use in clinical settings. Researchers aimed to develop a more practical, low-cost method with high sensitivity to detect genotype and RT mutations while detecting HBV DNA.
Related Content: Fluorescence Imaging System For Ovarian Cancer Surgery